Articles

1. Optimizing Clinical Trial Enrollment: Same Day Turnaround Of Blood Chemistry For Eligibility 5/22/2012

   Potential clinical trial participants and sponsors typically wait 2-3 days for lab results to determine eligibility. For the would-be participant every day that elapses could contribute to the loss of interest and increase the risk of losing a potential study subject for many reasons. By Paul S. Savuto, MS, MBA Blinded Diagnostics

2. Kemwell Biopharma Brochure 3/29/2012
   Kemwell Biopharma will offer services ranging from full-service process development, manufacture, formulation and fill and finish at the cGMP manufacturing facility in Bangalore, India as a one-stop-shop through access to Boehringer Ingelheim's® cell line development with the BI HEX technology platform, followed by a preferred access to the large-scale commercial production of Boehringer Ingelheim at its facilities in Europe.
3. Brochure: RHOBUST® Downstream Processing Technology 2/22/2012
   Rhobust® technology is a downstream processing technology for the manufacturing of recombinant proteins and antibodies.
4. Brochure: XD® Technology: Improve Biopharmaceutical Production 2/22/2012
   DSM's XD® Technology has been developed to drive yield improvements in the production of biopharmaceuticals.
5. Brochure: Finished Dosage Forms 2/21/2012
   DSM is a global provider of finished dosage form manufacturing and related services to pharmaceutical and biopharmaceutical markets.
6. Brochure: Biologics Contract Manufacturing & Technology Solutions 1/30/2012

   DSM provides turn-key biologic manufacturing solutions, contract manufacturing for preclinical development, clinical trials or commercial supply and reduced cost, risk, and time to market.

7. Integrative Biology: At The Tipping Point 10/7/2011

   I recently met Gustavo Salem, VP and general manager of the Biological Systems Division at Agilent Technologies. Salem believes integrative biology is at a tipping point for producing major breakthroughs in the drug development. By Rob Wright, Chief Editor, Life Science Leader magazine

8. White Paper: Foreign Clinical Trial Data 8/5/2011
   Given the high cost of moving a promising drug candidate through years of clinical trials, it’s no wonder that more and more drug manufacturers have begun conducting at least some of their clinical trials in foreign countries. With lower costs and shorter recruiting times, the use of foreign sites is appealing to all drug developers, but especially to those involved in generic and “fast-track” approval programs.
9. Case Study: Recruitment Expertise Reduces High Screen Failure Rate 5/11/2011
   The Quintiles team developed a profile of patients who would be more likely to fulfill criteria and distributed it to sites.
10. Targeting Oncology 5/11/2011
    In the search to improve cancer outcomes, each promising advance across the biopharmaceutical frontier comes with challenges as unique as the specific molecular pathway and individual genetic profile it targets.